Fairmount Funds Management LLC

CIK 0001802528 · WEST CONSHOHOCKEN, PA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

Fairmount Funds Management LLC reported 12 positions worth $1.51B as of June 30, 2026 (13F filed August 14, 2026). Largest holding: ORKA (23.3%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.51B
2026 Q2
Positions
12
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
97.6%
Est. Net Flow (Q)
2026 Q2
10 / 12 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1ORKAORUKA THERAPEUTICS INCSH$352.6M23.31%3,705,262
2DNTHDIANTHUS THERAPEUTICS INCSH$247.3M16.35%2,537,191
336322Q206DAMORA THERAPEUTICS INCSH$226.6M14.98%8,713,000
4COGTCOGENT BIOSCIENCES INCSH$213.0M14.08%5,503,418
5JBIOJADE BIOSCIENCES INCSH$101.2M6.69%4,553,494
6ELVNENLIVEN THERAPEUTICS INCSH$94.2M6.22%1,855,644
7VRDNVIRIDIAN THERAPEUTICS INCSH$93.5M6.18%5,090,928
8ZBIOZENAS BIOPHARMA INCSH$59.9M3.96%2,359,025
9CBIOCRESCENT BIOPHARMA INC.SH$49.5M3.27%2,747,866
1003770N101APOGEE THERAPEUTICS INCSH$39.6M2.62%298,647

The free plan shows the top 10 positions. The remaining 2 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Fairmount Funds Management LLC hold as of Q2 2026?

Fairmount Funds Management LLC reported 12 positions worth $1.51B in its Q2 2026 13F filing. Largest positions: ORKA (23.3%), DNTH (16.3%), DAMORA THERAPEUTICS INC (15.0%), COGT (14.1%) and JBIO (6.7%).

What did Fairmount Funds Management LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Fairmount Funds Management LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.